Rozanolixizumab for generalised myasthenia gravis

Rozanolixizumab is in clinical development for the treatment of generalised myasthenia gravis
(gMG). Myasthenia gravis (MG) is a long-term condition which causes certain muscles to become
weak and tire easily. It is caused by a problem with the immune system. In MG patients, harmful
IgG (immunoglobulin G) antibodies mistakenly attack healthy cells and tissues, causing weakness
and fatigue of voluntary muscles, meaning that the muscles are unable to tighten (contract).
Symptoms include drooping of the eyelids and double vision; swallowing, speaking and breathing
difficulties when muscles in the mouth, throat and chest are affected. Many commonly used
therapies in MG have important limitations such as late onset of action and various side effects
including increased risk of infection; therefore, alternative therapeutic options are needed for
gMG patients.